Aging Biomarkers Insights

David discusses innovative clinical trials aimed at modifying aging biomarkers to combat age-related diseases. He highlights the potential of using artificial intelligence to identify compounds that can influence inflammatory aging, revealing that some readily available compounds could decrease inflammatory age significantly in a short time. The conversation also touches on the challenges of altering epigenetic landscapes and the importance of regulatory milestones for bringing these insights to the public.